BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

  Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2023 revenue results, cash and investments at year end 2023, and provided 2024 guidance on select key financial metrics including net cash used in operations.

  January 7, 2024

   · 

  9 min read
• Job Trends

  Isomorphic Labs Announces Strategic Multi-Target Research Collaboration With Lilly

  Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, announced that it has entered into a strategic research collaboration with Eli Lilly and Company.

  January 7, 2024

   · 

  2 min read
• Genetown

  Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS

  Dewpoint Therapeutics Inc. announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis.

  January 7, 2024

   · 

  3 min read
• Business

  Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

  Exact Sciences Corp. announced that the company expects to report revenue between $645.5 million and $647.5 million for the fourth quarter ended December 31, 2023.

  January 7, 2024

   · 

  11 min read
• Biotech Bay

  IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance

  IDEAYA Biosciences, Inc. announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.

  January 7, 2024

   · 

  4 min read
• Business

  RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance

  RxSight, Inc. announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2023 and provided full-year 2024 guidance.

  January 7, 2024

   · 

  5 min read
• Calliditas to present at 42nd Annual JP Morgan Healthcare Conference

  Calliditas Therapeutics AB announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.

  January 7, 2024

   · 

  1 min read
• Drug Development

  Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix

  Curevo Vaccine announced positive data from an 876-patient Phase 2 trial of amezosvatein head-to-head versus Shingrix in participants aged 50 years and older.

  January 7, 2024

   · 

  6 min read
• QIAGEN announces plans to return approximately $300 million to shareholders

  QIAGEN N.V. announced a plan to return up to approximately $300 million to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split.

  January 7, 2024

   · 

  5 min read
• Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

  Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma A/S.

  January 7, 2024

   · 

  10 min read